Last reviewed · How we verify
Mirabegron 25mg
At a glance
| Generic name | Mirabegron 25mg |
|---|---|
| Also known as | Betmiga |
| Sponsor | Far Eastern Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Mechanisms for Activation of Beige Adipose Tissue in Humans (PHASE2)
- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease (PHASE4)
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (PHASE4)
- Does Mirabegron Increase the Body Heat Generated by the Nervous System (EARLY_PHASE1)
- Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (PHASE4)
- Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirabegron 25mg CI brief — competitive landscape report
- Mirabegron 25mg updates RSS · CI watch RSS
- Far Eastern Memorial Hospital portfolio CI